

Resource Summary Report

Generated by [RRID](#) on Aug 2, 2026

InVivoPlus mouse CTLA-4 (CD152)

RRID:AB_1107598

Type: Antibody

Proper Citation

Bio X Cell Cat# BE0032, RRID:AB_1107598

Antibody Information

URL: http://antibodyregistry.org/AB_1107598

Proper Citation: Bio X Cell Cat# BE0032, RRID:AB_1107598

Target Antigen: CTLA-4 (CD152)

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Flow cytometry
Consolidation on 12/2021: AB_1107598, AB_2894790.

Antibody Name: InVivoPlus mouse CTLA-4 (CD152)

Description: This monoclonal targets CTLA-4 (CD152)

Target Organism: mouse

Clone ID: clone UC10-4F10-11

Antibody ID: AB_1107598

Vendor: Bio X Cell

Catalog Number: BE0032

Alternative Catalog Numbers: BE0032-1MG, BE0032-5MG, BP0032-25MG, BP0032-50MG, BP0032-100MG, BE0032-100MG, BE0032-50MG, BE0032-25MG, BP0032-5MG

Record Creation Time: 20250819T230829+0000

Record Last Update: 20250820T042501+0000

Ratings and Alerts

No rating or validation information has been found for InVivoPlus mouse CTLA-4 (CD152).

No alerts have been found for InVivoPlus mouse CTLA-4 (CD152).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang J, et al. (2025) The transcription factor ZEB2 mediates the antitumor efficacy of tumor-infiltrating lymphocytes in non-small cell lung cancer. *Cell death & disease*, 16(1), 806.

Torres-Mejia E, et al. (2025) Lung Cancer-Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg-Dependent CD8+ T-cell Exclusion. *Cancer immunology research*, 13(4), 496.

Ifejeokwu OV, et al. (2024) Immune Checkpoint Inhibition-related Neuroinflammation Disrupts Cognitive Function. *bioRxiv : the preprint server for biology*.

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. *Cancer cell*.

Shao TY, et al. (2023) Kruppel-like factor 2+ CD4 T cells avert microbiota-induced intestinal inflammation. *Cell reports*, 42(11), 113323.

Guo M, et al. (2023) Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control. *Cell reports*, 42(9), 113047.

Won T, et al. (2022) Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. *Cell reports*, 41(6), 111611.

Limagne E, et al. (2022) MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. *Cancer cell*, 40(2), 136.

Morimoto J, et al. (2022) Aire suppresses CTLA-4 expression from the thymic stroma to control autoimmunity. *Cell reports*, 38(7), 110384.

Marangoni F, et al. (2021) Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. *Cell*, 184(15), 3998.

Rodriguez AB, et al. (2021) Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. *Cell reports*, 36(3), 109422.

Deng Y, et al. (2021) Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. *Nature communications*, 12(1), 7041.

Zenke S, et al. (2020) Quorum Regulation via Nested Antagonistic Feedback Circuits Mediated by the Receptors CD28 and CTLA-4 Confers Robustness to T Cell Population Dynamics. *Immunity*, 52(2), 313.

Hegde S, et al. (2020) Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. *Cancer cell*, 37(3), 289.

Miao Y, et al. (2019) Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells. *Cell*, 177(5), 1172.

Best SA, et al. (2018) Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment. *Cell metabolism*, 27(4), 935.